{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:05:44Z","timestamp":1789743944842,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bulcan.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:17:49Z","timestamp":1788866269000},"page":"1118-1126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-346X","authenticated-orcid":false,"given":"Barani","family":"Karikalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-5218","authenticated-orcid":false,"given":"Ye Htut","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-1856","authenticated-orcid":false,"given":"Shiueh Lian","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.04.016_bib0255","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12964-024-01863-9","article-title":"Targeting mutant p53: a key player in breast cancer pathogenesis and beyond","volume":"22","author":"Qayoom","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0260","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3390\/cancers17101614","article-title":"TP53 mutation-specific dysregulation of store-operated calcium entry and apoptotic sensitivity in triple-negative breast cancer","volume":"17","author":"Rabab","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0265","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0270","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in cancer: accumulation, gain-of-function, and therapy","volume":"429","author":"Yue","year":"2017","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0275","first-page":"e60125","article-title":"P53 gene as a promising biomarker and potential target for the early diagnosis of reproductive cancers","volume":"16","author":"Aswathi","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.20106","article-title":"The TP53 tumor suppressor gene: from molecular biology to clinical investigations","volume":"298","author":"Baliakas","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0285","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308807120","article-title":"Triple-negative breast tumors are dependent on mutant p53 for growth and survival","volume":"120","author":"Dibra","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0290","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/biom15020244","article-title":"The role of p53 mutations in early and late response to mitotic aberrations","volume":"15","author":"Hertel","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0295","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1158\/2767-9764.CRC-24-0128","article-title":"p53R172H and p53R245W hotspot mutations drive distinct transcriptomes in mouse mammary tumors through a convergent transcriptional mediator","volume":"4","author":"McDaniel","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0300","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/biom15091308","article-title":"Natural compounds as modulators of ferroptosis: mechanistic insights and therapeutic prospects in breast cancer","volume":"15","author":"He","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0305","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-23-0402","article-title":"Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0310","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.3390\/cancers16233899","article-title":"Clinical relevance of TP53 mutation and its characteristics in breast cancer with long-term follow-up date","volume":"16","author":"Hwang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0315","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0320","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0325","doi-asserted-by":"crossref","first-page":"102025","DOI":"10.1016\/j.tranon.2024.102025","article-title":"Targeting mutant p53 with arsenic trioxide: a preclinical study focusing on triple negative breast cancer","volume":"46","author":"Rajaram","year":"2024","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0330","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12520","article-title":"Cell fate regulation governed by p53: friends or reversible foes in cancer therapy","volume":"44","author":"Song","year":"2024","journal-title":"Cancer Commun"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0335","doi-asserted-by":"crossref","first-page":"104324","DOI":"10.1016\/j.critrevonc.2024.104324","article-title":"Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions","volume":"196","author":"Gerosa","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0340","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.3390\/ijms26125701","article-title":"Targeting WEE1 kinase for breast cancer therapeutics: an update","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0345","doi-asserted-by":"crossref","first-page":"e005068","DOI":"10.1136\/jitc-2022-005068","article-title":"Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0350","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/bioengineering11080830","article-title":"Advances in siRNA drug delivery strategies for targeted TNBC therapy","volume":"11","author":"Subhan","year":"2024","journal-title":"Bioengineering"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0355","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3390\/biomedicines10112843","article-title":"Immunotherapy against the cystine\/glutamate antiporter xCT improves the efficacy of APR-246 in preclinical breast cancer models","volume":"10","author":"Barutello","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0360","doi-asserted-by":"crossref","first-page":"102732","DOI":"10.1016\/j.nano.2024.102732","article-title":"Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery","volume":"56","author":"Kamath","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0365","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/biom12040548","article-title":"Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0370","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0375","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2012.44.0412","article-title":"Targeting mutant p53 in human tumors","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0380","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/ijms26031078","article-title":"Pharmacological inhibition of MDM2 induces apoptosis in p53-mutated triple-negative breast cancer","volume":"26","author":"On","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0385","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.30425","article-title":"Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?","volume":"140","author":"Synnott","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0390","doi-asserted-by":"crossref","first-page":"41363","DOI":"10.18632\/oncotarget.9133","article-title":"COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo","volume":"7","author":"Salim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0395","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(16)32638-7","article-title":"COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K\/AKT\/mTOR pathway","volume":"69","author":"Salim","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0400","doi-asserted-by":"crossref","first-page":"e13121","DOI":"10.1200\/JCO.2018.36.15_suppl.e13121","article-title":"Targeting mutant p53 with COTI-2: a new approach for the treatment of patients with triple-negative breast cancer?","volume":"36","author":"Synnott","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0405","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-019-05435-1","article-title":"COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells","volume":"179","author":"Synnott","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0410","doi-asserted-by":"crossref","first-page":"117351","DOI":"10.1016\/j.biopha.2024.117351","article-title":"Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer","volume":"179","author":"Qayoom","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0415","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","article-title":"Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator","volume":"15","author":"Puzio-Kuter","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0420","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41418-025-01549-w","article-title":"The roles of mutant p53 in reprogramming and inflammation in breast cancers","volume":"32","author":"Kummar","year":"2025","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0425","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0430","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-012-2378-9","article-title":"A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer","volume":"137","author":"Ma","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0435","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2017.09.053","article-title":"Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007","volume":"414","author":"Synnott","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0440","doi-asserted-by":"crossref","first-page":"984","DOI":"10.18632\/oncotarget.1070","article-title":"Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells","volume":"4","author":"Yi","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0445","doi-asserted-by":"crossref","first-page":"e0172832","DOI":"10.1371\/journal.pone.0172832","article-title":"Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant","volume":"12","author":"Simon","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0450","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1535-7163.MCT-20-0373","article-title":"Molecular targeting of RRM2, NF-kB, and mutant TP53 for the treatment of triple-negative breast cancer","volume":"20","author":"Wilson","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0455","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41419-024-06987-x","article-title":"Targeting of mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer","volume":"15","author":"Canu","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2025.5794","article-title":"Harnessing TP73-targeted nintedanib: a novel strategy to halt triple-negative breast cancer via p53-PPARa\/PI3K-Akt pathway suppression","volume":"67","author":"Zou","year":"2025","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0465","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1535-7163.MCT-24-0928","article-title":"Coinhibition of aurora kinase B and SUV4-20H induces synthetic lethality in wild-type p53-deficient cancer cells","volume":"24","author":"Duan","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0470","doi-asserted-by":"crossref","first-page":"e0120936","DOI":"10.1371\/journal.pone.0120936","article-title":"Dual targeted therapy with p53 siRNA and epigallocatechingallate in a triple negative breast cancer cell model","volume":"10","author":"Braicu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0475","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00210-022-02316-1","article-title":"Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer","volume":"396","author":"Liu","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0480","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1007\/s00210-025-03805-9","article-title":"The novel piperine derivative MHJ-LN inhibits breast cancer by inducing apoptosis via p53 activation","volume":"398","author":"Ren","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0485","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3892\/or.2014.3665","article-title":"Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0490","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001677","article-title":"Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events","volume":"3","author":"Meissner","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0495","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/oncolo\/oyac281","article-title":"Therapeutic role of tamoxifen for triple-negative breast cancer: leveraging the interaction between ERb and mutant p53","volume":"28","author":"Scarpetti","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2026.04.016_bib0500","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11684-023-1016-8","article-title":"Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study","volume":"18","author":"Wang","year":"2024","journal-title":"Front Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:18:54Z","timestamp":1789741134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0007455126003206"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}